March 20, 2001 |
Investors swept up shares of NeoTherapeutics Inc. on Monday after the Irvine biopharmaceutical company announced a license agreement with Pfizer Inc. worth up to $12 million. NeoTherapeutics, which until now has not generated revenue, will receive an initial payment from Pfizer.
February 8, 2001 |
NeoTherapeutics Inc.'s climbing stock moved up an additional 30% Wednesday, snapped up by investors after the company said it is planning a pivotal study of its drug compound for treating Alzheimer's disease. The Irvine biopharmaceutical company also said this week that a subsidiary received $7 million in new financing. The stock, which rose 15% on Tuesday and 14% on Monday, closed Wednesday at $4.16, up 97 cents a share in Nasdaq trading. A total of 1.
January 3, 2001 |
NeoTherapeutics Inc. filed a shelf registration statement with the Securities and Exchange Commission to issue up to $50 million of debt securities, stock, depositary shares or warrants. The Irvine biopharmaceutical company said Tuesday the filing allows it "speed and flexibility" when market conditions are attractive. A shelf filing lets the company register securities in advance and sell them from time to time as needed.
November 4, 2000
The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.
August 22, 2000 |
NeoTherapeutics Inc., an Irvine pharmaceuticals company, said Monday that Rajesh C. Shrotriya has been named president, effective Sept. 1. A company spokeswoman said Shrotriya assumes the post from Alvin Glasky, who will remain chief executive, chairman and chief scientific officer. In a news release Monday, the company said Shrotriya was most recently executive vice president and chief scientific officer of SuperGen Inc.
August 15, 2000
NeoTherapeutics Inc., an Irvine developer of treatments for neurological and psychiatric diseases, reported a second quarter net loss of $12.3 million, or $1.29 a share, which included a $1-million noncash accounting charge related to the sale of debentures. The net loss for the prior year totaled $4.1 million, or 63 cents a share. No revenue was recorded.